No, the earlier date (January) was my own calculations from the the date the FDA submission was lodged (which is typical for a medical device such as Cardiocel.) I then checked my own figures with an employee at the company who agreed with them, so I don't know why mid next year is the expected date although at the end of the day it's not of great importance.
- Forums
- ASX - By Stock
- AVR
- annual general meeting review
annual general meeting review, page-16
-
-
- There are more pages in this discussion • 39 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
(20min delay)
|
|||||
Last
$12.15 |
Change
0.350(2.97%) |
Mkt cap ! $256.8M |
Open | High | Low | Value | Volume |
$11.80 | $12.15 | $11.21 | $376.0K | 32.22K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 139 | $12.00 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$12.15 | 830 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 841 | 11.900 |
1 | 1000 | 11.800 |
1 | 5000 | 11.720 |
1 | 2 | 11.260 |
1 | 8 | 11.220 |
Price($) | Vol. | No. |
---|---|---|
12.150 | 830 | 1 |
12.250 | 175 | 1 |
12.400 | 198 | 1 |
12.800 | 1000 | 1 |
12.850 | 1000 | 1 |
Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
Featured News
LU7
Discover the strong preliminary feasibility of the Bécancour Lithium Refinery, showcasing resilience in a low pricing environment and a strategic plan to capitalize on future price recoveries
AVR (ASX) Chart |